Peter Holmer-Bretlau joins Skarbek as Principal Consultant
Experienced healthcare consultant Peter Holmer-Bretlau has joined Skarbek Associates. As the firm’s newest Principal Consultant, he brings a wealth of expertise and life-sciences industry insights to the team.
A statement from Skarbek Associates read, “Peter has a proven ability to lead complex strategic initiatives, deliver tangible results and navigate diverse global market challenges. His deep understanding of operational efficiency and cross-functional team development will undoubtedly add tremendous value to our clients.”
Skarbek Associates is an international strategy implementation and advisory firm, which helps clients to grow and compete successfully and sustainably through the successful execution of strategic initiatives. Looking ahead, Peter Holmer-Bretlau will be supporting Skarbek clients to define, refine and implement innovation driven strategies for growth.
His arrival comes as challenges relating to the pandemic, budget shortfalls, and demographic shifts in the population place strain on the world’s healthcare systems. As Skarbek looks to support clients in the sector navigate these problems, Holmer-Bretlau will work closely with organisations to offer expert guidance on strategy implementation and operational improvement.
Prior to joining Skarbek, Holmer-Bretlau held key leadership roles at GSK, Novartis and also ViiV. His commercial experience spans all facets of strategy conception and implementation including product launch, portfolio management, turn-around performance and building high-performing teams. He is an expert facilitator of projects and workshops and engaging the wider organisation.
Skarbek’s statement added, “We look forward to working with Peter as we continue to help organisations navigate complexities and achieve sustainable growth through successful strategy implementation.”
Earlier in the spring, Skarbek also appointed a new Senior Advisor. Paul Dove joined the firm, bringing deep experience and expertise in innovation, research and development and organisational growth.
